Invesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNX

Key Points

• Invesco Ltd. increased its stake in REGENXBIO Inc. by 52.4%, acquiring an additional 27,341 shares, bringing its total ownership to 79,469 shares valued at approximately $568,000.
• Institutional investors own 88.08% of REGENXBIO, with significant increases in holdings from firms like Millennium Management and Vanguard Group during recent quarters.
• REGENXBIO reported a quarterly earnings loss of ($1.38) per share, missing the consensus estimate, and had revenue of $21.36 million, below expectations of $40.87 million.

Invesco Ltd. increased its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 52.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,469 shares of the biotechnology company's stock after purchasing an additional 27,341 shares during the period. Invesco Ltd. owned approximately 0.16% of REGENXBIO worth $568,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in REGENXBIO during the fourth quarter worth $568,000. Dimensional Fund Advisors LP increased its position in shares of REGENXBIO by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock worth $9,054,000 after acquiring an additional 21,234 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of REGENXBIO by 442.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 10,714 shares during the last quarter. Stifel Financial Corp lifted its position in REGENXBIO by 26.5% in the 4th quarter. Stifel Financial Corp now owns 188,844 shares of the biotechnology company's stock valued at $1,460,000 after acquiring an additional 39,564 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 1,982 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Stock Performance

NASDAQ:RGNX traded down $0.32 during trading on Wednesday, reaching $9.57. The company's stock had a trading volume of 438,786 shares, compared to its average volume of 602,101. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $13.48. The firm has a market cap of $483.38 million, a price-to-earnings ratio of -2.78 and a beta of 1.17. The firm has a 50 day moving average of $8.73 and a 200-day moving average of $8.22.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). The business had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. Equities research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGNX has been the subject of several analyst reports. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and set a $34.00 price target on shares of REGENXBIO in a report on Monday. Chardan Capital reissued a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Monday. Barclays dropped their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Finally, Royal Bank Of Canada reduced their target price on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.38.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.